

EU Health Programme Funding

An SME Perspective



Summary of Presentation

- FP7 / Health programme
- BioKinetic's current project:
NeoStrep
- Horizon 2020



FP7 introduction

- Knowledge lies at the heart of the European Union's Lisbon Strategy to become the " **most dynamic competitive knowledge-based economy in the world** "
- The ' **knowledge triangle** ' - **research, education and innovation** - is a core factor in European efforts to meet the ambitious goals

Specific Programmes

- **Cooperation** — Provides project funding for collaborative, translational research. Organised through themes such as health, energy, transport.
- **Ideas** — Provides project funding for individuals and teams engaged in frontier research
- **People** — Funds actions to improve training, career development, and mobility of researchers between sectors and countries worldwide
- **Capacities** — Funds actions designed to improve Europe's research infrastructure and the research capacity of SMEs

FP7 Health objectives

- Improving the health of European citizens
- Increasing the competitiveness and boosting innovative capacity of EU health related industries and businesses
- Addressing global health issues including emerging epidemics

FP7 programme

- FP7 ran 2007-2013
- Health budget (part of cooperation theme): €6 100 million (2007 - 2013)
- Collaborative approach to translational research
- Calls for participation




Calls for participation

- Medical Research
- Infectious Diseases
 - Drugs and vaccines for infections that have developed or are at risk of developing significant antimicrobial resistance (NeoStrep)
- Public Health
- Innovative Medicines Initiative
- Biotechnology, tools and technologies
- Large scale data gathering & systems biology

European Funding Success Factors for BioKinetic

- SME – eligible for larger portion of grant assistance, lean & flexible operations suited to early phase
- UK based – need 3 MS to form a consortium
- Clinical trial specialists with specific expertise in women's health studies and vaccine work
- FP7 project worth €2m to BioKinetic
- Second H2020 project pending c. €9m

NeoStrep consortium members



The Clinical Trial

Title, *'Development of Group B Streptococcal Vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention'*

- 6 separate work packages from identifying optimal adjuvant formulation, dose and dosing regimen for the vaccine in preparation for initiating clinical trials to dissemination of information.
- Timeline for Conduct: *June 2015*, demographic for clinical trial: *280 Healthy Women, aged 18-40*

Work Packages

- WP1 - Non-Clinical (Lund/MinervaX)
- WP2 – Manufacturing (Lund/MinervaX - Biovian)
- WP3 – Toxicology Studies (ScanTox)
- WP4 - Clinical Trials (BioKinetic)
- WP5 - Dissemination & Exploitation (MinervaX)
- WP6 – Consortium Mgt and Reporting (Lund)

The Clinical Trial

Part A - Primary Objective

To evaluate the safety and tolerability of the GBS-NN vaccine, by analysis of local and systemic reactogenicity, and adverse event profiling.

Part B - Primary Objective

To evaluate the antibody response induced by different GBS-NN vaccine dose regimes 12 weeks following the first dose in healthy female volunteers.

Why is this trial important?

- GBS is a common cause of life-threatening infections in newborns
- Threat of emerging resistance to antibiotic prophylaxis
- Other GBS vaccine in development has less serotype coverage (60-70%) than the NeoStrep one (95%)
- Novel protein-only strategy
- Other GBS vaccine requires one primary dose, 2 boosters; this will require 1 booster only
- Simpler production method developed to reduce costs

Transparency requirements


- Input from advocacy groups
- Dissemination and awareness of information
 - Presentation and public support from Northern Irish Health Minister
- Transparency and stakeholder input. Impact on trial design
- Example: use of adjuvant

GBSS Group NI



EU contribution


EU Contribution - 2007-2014 (June)



Current R&D Funding uptake



Figure 23: Regional performance groups



The EU Member States Cyprus, Estonia, Latvia, Lithuania, Luxembourg and Malta are not included in the RIS analysis. Group membership shown is that of the IUS. Map created with Region Map Generator.

Participation by type of organisation

- Higher or secondary education institutes are main beneficiaries of FP7
 - » UK, Germany, Netherlands, Sweden
- Industry/private-for-profit
 - » France, Germany, Italy, Spain
- Public body
- Research organisations
- Other

Horizon 2020

- How it differs

- » FP7 focused on regional innovation
- » H2020 focuses on innovation through institutions, companies, people

- Why get involved

- » Consultants to facilitate process
- » New business model / funding stream
- » New contacts and relationships built

- How to get involved

- » Registration/participation in online networks, e.g. Enterprise Europe Network, Fit for Health 2.0 events

Horizon 2020

Three distinct, mutually reinforcing priorities:

- 1 **Excellent Science, €24 billion.** Investment in European Research Council.
- 2 **Competitive Industries, €18 billion.** Targeted support on key enabling and industrial technologies that underpin innovation across different industries and sectors
- 3 **Better Society, €32 billion.** Six challenges: Health; demographic change and wellbeing; Food security; sustainable agriculture etc

Horizon 2020

Research 'Calls' focus on:

- 1) Understanding health, ageing and disease
- 2) Effective health promotion, disease prevention, preparedness and screening
- 3) Improving diagnosis
- 4) Innovative treatments and technologies
- 5) Advancing active and healthy ageing
- 6) Improving health information, data exploitation and providing an evidence base for health policies and regulation

Emphasis on 'Connected Health' – moving healthcare beyond the hospital and clinic for patient care

Horizon 2020

- 1 The total budget will go up from €50 billion to €80 billion (Duration 2014-2020)
- 2 100% of direct costs will be funded up to Phase II, 70 % thereafter.
- 3 20% flat rate of indirect costs as a proportion of direct costs
- 4 Strong focus on SME's going forward and particularly from less favoured areas (e.g. N Ireland)

Useful Websites

- www.ec.europa.eu/research/horizon2020/index_en.cfm (H2020 Website)
- www.healthcompetence.eu – info on all EU research 7 results
- www.echalliance.com (European Connected Health Alliance – emphasis on connected health)
- www.enterpriseeuropeni.com (Largest EU funded business support network – opportunities database)
- www.fitforhealth.eu (new partner search)
- www.errinnetwork.eu (new partner search)
- www.connect.innovateuk.org (TSB -find innovators on and other funding options)
- http://ec.europa.eu/research/participants/data/ref/h2020/wp/2014_2015/main/h2020-wp1415-health_en.pdf (Work Programme 8 - Health & Wellbeing)

Enterprise Europe Network example



Technology Offer

Save

Last updated 2014-07-23 11:21:18

Internal reference

BioK1

?

Title*

Northern Irish Contract Research Organisation (CRO) offering insightful clin

?

Summary*
(Max 500 chars)

A Northern Ireland based Contract Research Organisation (CRO) in the clinical pharmacology sector is looking for partners in the pharmaceutical and medical device sectors who require advice, design and conduct of clinical trials or testing of new products or devices.

?

233

Description*
(100-4000 chars)

The company is a Contract Research Organisation (CRO) located in Belfast, Northern Ireland. BioKinetic provides clinical research to the highest standards, working to ICH-GCP guidelines and having obtained Supplementary Accreditation from the Medicines & Healthcare Products Regulatory Agency (MHRA), the UK's competent authority.

?

949

Services offered include: Protocol development, Investigational Medicinal Product Dossier (IMPD) and Investigator's Brochure (IB)

Advantages and innovations*
(50-2000 chars)

- Independent, owner-managed SME since 1996
- Currently a partner in an FP7 project (Responsible for clinical trials, Phase I, and IIa developing a Group B Strep vaccine)
- Experience in successful European funding applications and reporting
- Favourable UK regulatory environment (14 day approval timeline for Phase I trials)
- Recruitment capability of the whole of Ireland
- In-house and outpatient capability

?

498

Example of an offer (last week)

Services Survey

Enquiry Service

Partners

- Successful partnerships

- Search offers

- Disseminate offers

- What's hot

eZine and alerts

Hot Topics

Tenders Alert Service

Have Your Say in Europe

RSS Feeds

Network region









Search offers

H2020-SFS-16-2015. Innovative products to improve elderly people's health (RDES20141007001)

Summary

A Spanish SME is willing to submit a H2020-SFS-16-2015 proposal project. The project aims to develop innovative ingredients for new products in order to treat malnutrition in elderly population. A Research centre, University or SME is being sought to coordinate this project.

-  Enquire about this opportunity
-  Back to profile list
-  Download as PDF
-  Send to a friend
-  Show me similar profiles (4)

 **SPAIN**
Research partner request
Created: 08/10/2014
Last updated: 22/10/2014

Full description

The European project aims to propose a development of a wide variety of products made from innovative ingredients. This products will be designed to improve the health of the elderly through nutritional management, such as high intake of proteins, essential vitamins and minerals, reduction of the glycemic index, reinforcement of the immune system and regulation of intestinal transit, etc.

The project, which will be developed in order to treat malnutrition, as well as many other disorders, will also include the clinical validation of the beneficial effects of the products.

The company has experience in the design of food products and it has collaborated with several relevant food companies related elderly nutrition. Therefore, it is capable to achieve the project's objectives.

Conclusion

- 1 Get involved – register on websites, attend events, network.
- 2 Don't fall at first hurdle – perception that application is complicated; this gets easier once process is known.
- 3 Watch the snowball roll – once you are known to participants and EU, repeat consortia opportunities arise.

(Slides available)

Thank you!